Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
-
Canada's Davies 'available' for historic knockout clash
-
Ryu takes one-shot lead over Henderson at Women's PGA Championship
-
Hovland seizes one-shot PGA Travelers lead over Scheffler
-
Jangoo and Chase put West Indies in control against Sri Lanka
-
Mauvaka double inspires Toulouse to fourth-straight Top 14 in storm-impacted final
-
World Cup star Gakpo requests privacy after death of unborn son
-
Solidarity, sadness among Venezuelans made destitute by quake
-
Aid planes landing at partially reopened Venezuela airport after quakes
-
Iran says US violated peace deal as both sides attack
-
Spain's Williams hits out at Uruguay over World Cup injury
-
'We need help': Venezuelans furious at slow official response to quakes
-
World's largest particle smasher halts for upgrade to boost hunt for dark matter
-
Venus Williams relishes 'very special' Wimbledon reunion with sister Serena
-
Ex-Olympic medallist Canderloro elected French Ice Sports chief
-
Ravindra leads New Zealand rally in England finale after Archer's double strike
-
Prince Harry and family to stay at royal residences on UK visit
-
Wimbledon 'towel thief' Swiatek back on the trophy hunt
-
'Why not?': Cape Verde eye seismic World Cup shock against Argentina
-
Venezuela earthquake deaths near 1,000, with millions more in need
-
Russell snatches controversial pole in Austria after Verstappen crash
-
French Open champs head to Wimbledon wrestling with new-found status
-
Davidovich Fokina wins in Mallorca for first ATP title
-
Budapest Pride marchers push for equality after reversed ban
-
Sabalenka urges Grand Slams to 'get it done' in prize money boycott row
-
Russell snatches pole, Antonelli fourth for Austria GP grid
-
Russell snatches pole as Verstappen, Antonelli fourth for Austria GP grid
-
Broos smiles and snarls before South Africa's historic World Cup match
-
Smith and supersub Foulkes strike for New Zealand in England finale
-
Newborn baby rescued from rubble of Venezuela quake
-
Supersub Foulkes strike for New Zealand in England finale
-
Raducanu halts practice session to put Wimbledon bid in doubt
-
Wolff says Russell will be at Mercedes next season
-
Keys beats Maria to clinch third Eastbourne title
-
Djokovic inspired by Serena as he targets history at Wimbledon
-
Thousands ride through Rome as Vespa celebrates 80 years
-
Stokes falls cheaply as England collapse in New Zealand decider
-
Sinner ready for Wimbledon defence despite lack of time on grass
-
Russell bounces back to beat Antonelli in final practice
-
Records tumble as European heatwave moves east
-
Iran says US violated peace deal as both sides trade fire
-
England, Portugal eye top spots as World Cup group stages wrap up
-
Injured Australian pair Leckie, Italiano out of World Cup
-
US, Iran trade strikes putting new strain on Middle East truce
-
Farmers fear drought as Italy's longest river runs dry
-
Thousands expected as Vespa celebrates 80 years in Rome
-
Budapest Pride to push for equality after reversed ban
-
Pino, Williams injuries mar Spain's World Cup progress
-
World Cup fans get taste of American life -- at the mall
-
'Struggle continues' in Bolivia's Morales heartland
-
World Cup turns New York's Times Square into global fan hub
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026, in Chicago, IL.
The accepted abstract, titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy," highlights preclinical research supporting Xenetic's DNase-based therapeutic approach designed to enhance CAR T-cell activity and improve antitumor responses.
Presentation Details:
Session Title: Hematologic Malignancies - Plasma Cell Dyscrasia (Poster Session)
Abstract Title: Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy
Poster Board: 410
Presentation Date & Time: June 1, 2026, 9:00 AM - 12:00 PM CDT
Presenter: Alexey V. Stepanov, PhD
The poster will be available to conference attendees during the scheduled session. For more information, please visit asco.org.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
CONTACT:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
H.Romero--AT
